ADC 下一代 — 载荷创新
zanidatamab 新辅助 · 无化疗 pCR 30%，HER2 下调 56%
这是来自 AACR 的突发报道。AACR 是全球最大的癌症研究会议之一。根据 2 期 NeoZanHER 试验的结果，抗 HER2 双特异性抗体 zanidatamab 可能会作为 HER2 阳性癌症的新辅助疗法发挥作用
热度 7 · 7 赞 · 0 回复 · 0 转发
Ankur Karmokar, Emanuele Loro, Al Hassan Kyakulaga, Desmond Lau, Nina Weisser, Genevieve Desjardins, Prajwal Raghunatha, Edwin Clark, Robin Humphreys, Kedar S. Vaidya
读摘要原文 →Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam
读摘要原文 →Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam
读摘要原文 →来源：がんナビ通信 · x.com